MoonLake Immunotherapeutics Class A MLTX 深 沪
已收盘 10-30 16:00:00 美东时间
11.78
-0.790
-6.28%
华盛通- 最 高12.6296
- 今 开12.44
- 成交量 112.85万股
- 最 低 11.71
- 昨 收 12.57
- 总市值 10.03亿
- 52周最高 23.29
- 市盈率 静 --
- 换手率 1.33%
- 52周最低 9.46
- 委 比 73.08%
- 总股本 8510.67万
- 历史最高 64.98
- 量 比 0.58
- 振 幅 7.32%
- 历史最低 4.25
- 每 手 1
- 风险率 2.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
MoonLake Immunotherapeutics (NASDAQ:MLTX) stock is trading higher on Thursday with a session volume of 4.20 million compared to the average volume of 1.494 million, according to Benzinga Pro data. Analyst Questions AbbVie Efficacy Against Existing Benchmarks The jump comes in reaction to topline dat...
10-23 02:23
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
U.S. stocks were lower, with the Nasdaq Composite falling around 500 points on Thursday. Shares of Healthcare Services Group Inc (NASDAQ:HCSG) rose sharply following strong quarterly earnings. Healthcare Services reported quarterly earnings of 36 cents per share which beat the analyst consensus esti...
10-22 22:29
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $50 price target.
10-05 19:59
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
财报速睇 | MoonLake Immunotherapeutics Class A 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.62亿美元，同比亏损扩大11.9%
华盛资讯8月10日讯，MoonLake Immunotherapeutics Class A公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.62亿美元，同比亏损扩大11.9%。
08-10 20:04
财报速睇 | MoonLake Immunotherapeutics Class A 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.62亿美元，同比亏损缩窄11.3%
华盛资讯8月10日讯，MoonLake Immunotherapeutics Class A公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.62亿美元，同比亏损缩窄11.3%。
08-10 19:37
MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 (...
08-10 19:16
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 3.45 percent increase over losses of $(0.87) per share from the same period last year.
08-10 19:12
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
